Oncology and Hematology - Prova Education

1-16 of 139

Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
CME/CE
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD; Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
- Enriqueta Felip, MD
- Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
CME/CE In-Person & Virtual Event
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
May 30, 2026
Chicago, Illinois
1.50 credits
The Future of HNSCC: Aligning Teams, Transforming Care
The Future of HNSCC: Aligning Teams, Transforming Care
CME/CE
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD; Nancy Lee, MD, FASTRO
0.25 credits
- Ravindra Uppaluri, MD, PhD
- Nancy Lee, MD, FASTRO
0.25 credits
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
CME/CE
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
María-Victoria Mateos, MD, PhD
0.25 credits
- María-Victoria Mateos, MD, PhD
0.25 credits
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Kevin J Harrington, PhD, FRCP, FRCR, FRSB; Cristina Rodriguez, MD
0.50 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Cristina Rodriguez, MD
0.50 credits
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
María-Victoria Mateos, MD, PhD; Luciano Costa, M.D., Ph.D.
0.25 credits
- María-Victoria Mateos, MD, PhD
- Luciano Costa, M.D., Ph.D.
0.25 credits
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
MinuteCE®
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
Eileen M. O'Reilly, MD
0.75 program credits
- Eileen M. O'Reilly, MD
0.75 program credits
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
RAS Across Tumors: Who to Test When
RAS Across Tumors: Who to Test When
MinuteCE®
RAS Across Tumors: Who to Test When
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 credits 8 episodes
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 credits 8 episodes
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
Kathryn Arbour
0.75 program credits
- Kathryn Arbour
0.75 program credits
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Eileen M. O'Reilly, MD; Kathryn Arbour
0.75 program credits
- Eileen M. O'Reilly, MD
- Kathryn Arbour
0.75 program credits
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CE
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB; Christophe Le Tourneau, MD, PhD
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits

Prev
1
2
3
…
8
9
Next

1/6